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Abstract
Deletions within the neurexin 1 gene (NRXN1; 2p16.3) are associated with autism and have also
been reported in two families with schizophrenia. We examined NRXN1, and the closely related
NRXN2 and NRXN3 genes, for copy number variants (CNVs) in 2977 schizophrenia patients and
33 746 controls from seven European populations (Iceland, Finland, Norway, Germany, The
Netherlands, Italy and UK) using microarray data. We found 66 deletions and 5 duplications in
NRXN1, including a de novo deletion: 12 deletions and 2 duplications occurred in schizophrenia
cases (0.47%) compared to 49 and 3 (0.15%) in controls. There was no common breakpoint and the
CNVs varied from 18 to 420 kb. No CNVs were found in NRXN2 or NRXN3. We performed a
Cochran–Mantel–Haenszel exact test to estimate association between all CNVs and schizophrenia
(P = 0.13; OR = 1.73; 95% CI 0.81–3.50). Because the penetrance of NRXN1 CNVs may vary
according to the level of functional impact on the gene, we next restricted the association analysis
to CNVs that disrupt exons (0.24% of cases and 0.015% of controls). These were significantly
associated with a high odds ratio (P = 0.0027; OR 8.97, 95% CI 1.8–51.9). We conclude that NRXN1
deletions affecting exons confer risk of schizophrenia.
INTRODUCTION
Copy number variants (CNVs) are emerging as an important genomic cause of disease,
particularly autism where large de novo CNVs may account for up to 10% of cases (1-3). These
CNVs appear to be highly deleterious and may account for the dramatically reduced fecundity
in autism; in line with autistic individuals, schizophrenics have fewer children on average than
the general population and risk increases with paternal age (4,5). It also appears that the same
CNVs can increase susceptibility to more than one psychiatric phenotype (6). Because of this,
CNVs are also strong candidates for involvement in the aetiology of schizophrenia.
The role of CNVs in schizophrenia is less well documented, but there are classical examples
such as the translocation disrupting the DISC1 gene in a large Scottish pedigree (7) and velo-
cardio-facial syndrome (VCFS), caused by a large deletion at 22q11 which is associated with
psychosis in ~30% of cases (8). Several recent papers have also indicated that there might be
further schizophrenia associated CNVs, especially de novo deletions and duplications (9-14).
Both Kirov et al. (9) and Walsh et al. (11) investigated individuals with schizophrenia in order
to identify microdeletions and microduplications >100 kb potentially associated with the
disease. Each study found a deletion disrupting the neurexin 1 gene (NRXN1) at 2p16.3 in one
family, in a mother and two affected siblings, and identical twins concordant for child-onset
schizophrenia, respectively. However, neither was able to determine the prevalence,
penetrance or odds ratio of these CNVs because of their rarity and the small population size
examined. CNVs in NRXN1 have also previously been implicated in autism and mental
retardation (6,15-19). In the present study, we assessed the association of NRXN1 CNVs with
schizophrenia as part of a genome-wide scan in a sample of 2977 schizophrenia patients and
33 746 controls from seven European populations (Iceland, Finland, Norway, Germany, The
Netherlands, Italy and UK) using microarray data.
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RESULTS
For the NRXN1 locus on 2p16.3, we limited our search to include the region between Mb 49.90–
51.50 (Human Genome build36), encompassing all exons of NRXN1 and several hundred
kilobases of the upstream sequence. For comparison, the deletions reported in schizophrenic
patients by Kirov et al. (11) spans Mb 51.04–51.29 (Genome build36, 250 Kb) and the deletion
reported by Walsh et al. (13) Mb 50.023–50.137 (Genome build 36, 115 kb). Similarly, we
examined the interval for deletions or duplications and tested for their enrichment in
schizophrenia (see Materials and Methods section, CNV detection subsection).
We examined the region in 2977 schizophrenia patients and 33 746 controls from seven
European populations (Iceland, Finland, Norway, Germany, The Netherlands, Italy and UK)
(Supplementary Material, Table S1). We found 61 NRXN1 deletions, including a de novo
deletion, and 5 duplications in the combined sample (Fig. 1). The CNVs were found throughout
the locus, and varied, plus a further five deletions in subjects excluded from the controls (a
subject with autism, three subject with alcohol dependence and one first degree relative of a
schizophrenia subject) in size from 18 to 420 kb, with no common breakpoint, although some
single breakpoints may be shared. We found no obvious sequence elements such as low copy
repeats (LCRs) in the region that could mediate the rearrangements. In contrast, there were no
deletions or duplications found at the NRXN2 (11p13.1) or NRXN3 (14q31.1) loci, which were
searched for using an identical strategy.
We found 12 deletions and 2 duplications of NRXN1 in cases (0.47%) compared to 49 and 3
(0.15%) in the controls, all of which encompassed part of the NRNX1 gene or its promoter (Fig.
1). The most common deletion was found in 27 samples including one homozygote. One of
these was schizophrenic, and two had a diagnosis of alcoholism; the remainders were controls
(Supplementary Material, Table S2). Haplotype background suggests that all carriers for the
common deletion derive from a single founder. A further six deletions and one duplication
were seen in two, three and four samples, respectively, while 24 deletions and one duplication
were only observed once.
We performed Cochran–Mantel–Haenszel exact test to estimate association between all
deletions and duplications and schizophrenia. This analysis gave suggestive results, P = 0.13
(OR = 1.73; 95% CI 0.81–3.50) for all NRXN1 CNVs in schizophrenia versus controls. Because
it is likely that the pathogenicity and penetrance of CNVs at this locus vary, depending on the
functional effect they have on the gene, we next restricted the association analysis to those
CNVs which disrupt exons (Fig. 2). We found seven in cases (0.24%) and five in controls
(0.015%); these were more strongly associated with schizophrenia and had a higher odds ratio
(P = 0.0027; OR 8.97; 95% CI 1.8–51.9).
Because almost half of the cases (but not controls) with CNVs were from Germany (6/14), we
analysed haplotypes in the 5′ region of the NRXN1 gene region to see if we could detect
evidence of a common ancestor for these six CNVs; however, there was no evidence for
haplotype sharing in the region, unlike the haplotype sharing observed for the common small
deletion, supporting the notion that the majority of CNVs at this locus are not derived from a
founder.
There was no sex difference among carrier subjects; CNVs were found in eight female and six
male schizophrenia subjects, 31 female and 21 male controls. CNV type, geographic origin,
SNP boundaries, position (Human genome build 36) size, phenotype and sex are shown in
Supplementary Material, Table S2. In addition to the deletions in patients with schizophrenia
and control subjects with no known mental illness, there were five further deletions found in
the Icelandic population, in a subject with autism, three subjects with alcohol dependence and
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one first degree relative of a schizophrenia subject who did not participate in this study. These
subjects are shown in Figure 1, but were not included in the statistical analysis.
The clinical characteristics of the deletion subjects are shown in Table 1; there seems to be
nothing remarkable about these cases. We also tested allelic association for all SNP markers
in the 2p16.3 region studied here but no marker remained significantly associated at the 5%
level after correction for number of performed tests (data not shown).
To address the issue of the role of splicing in NRXN1 deletions, we reviewed all available
genomic data across the NRXN1 locus for evidence of alternative NRXN1 isoforms and
identified EST and cDNA transcript evidence to support two additional isoforms, which share
many exons with NRXN1a, which we term NRXN1a-2 and NRXN1 a-3 (Fig. 3). The
NRXN1a-2 isoform shares exons 6–14 with NRXN1a, but employs alternative first and last
exons. These alternative exons allow for distinct expression analysis of the NRXN1a-2 isoform,
using probe 1558708_at on the Affymetrix HG-U133_Plus_2.0 GeneChip (Supplementary
Material, Fig. S1c). This shows very low expression of NRXN1a-2, predominantly in the brain,
compared to much higher brain-specific expression of NRXN1a and NRXN1b (Supplementary
Material, Figs S1a and S1b). The NRXN1a-2 isoform has no signal peptide and no
transmembrane domain; however, it does contain Laminin G domains 2–4 and EGF domains
2 and 3 (Fig. 3). Evidence for the NRXN1a-3 isoform is much less conclusive as it shares all
exons with exons 4–18 of NRXN1a.
DISCUSSION
In the present study, we used 2977 schizophrenia patients and 33 746 controls, from seven
European populations, to examine CNVs at the neurexin 1 locus on 2p16.3. Deletions at this
locus have previously been associated with autism and mental retardation (6,15-19), and
deletions were also found in two families with schizophrenia. In addition, we examined the
other two known neurexin genes, NRXN2 (11p13.1) and NRXN3 (14q31.1) to see if they also
harbour potentially pathogenic deletions. Kirov et al. (9) screened 93 cases, and found a
deletion at 2p16.3 in one affected proband, as well as the unaffected mother and an affected
sibling. Walsh et al. (11) found a different deletion disrupting NRXN1 in identical twins
concordant for childhood-onset schizophrenia. However, because of the small sample size
employed, it is not possible to determine extent of association and the prevalence and odds
ratio for disease risk from their data. In our study population, we found an excess of CNVs in
the NRXN1 gene in schizophrenia, 0.47% of cases compared to 0.15% of controls, which did
not reach statistical significance. Conditioning on exon disrupting deletions or duplications
(i.e. those more likely to be pathogenic), the association became significant (P = 0.0027; OR
8.97, 95% CI 1.8-51.9) indicating that CNVs in the region may have different pathogenicity
or penetrance. There were no CNVs detected in the NRXN2 or NRXN3 loci, indicating that
deletion or duplication of either of these genes is not a significant factor in disease.
De novo versus segregating deletions
One of the 2p16.3 deletions reported here (autistic subject, Supplementary Material, Table S2),
was also found de novo in the Icelandic population (12), and the remaining rare deletions
probably occur de novo because they do not show any evidence of a founder effect and the
boundaries differ between individuals. However, we cannot be sure of this as in the present
study, the majority of cases with deletions do not have parents and other relatives available for
analysis. In contrast, the smallest common deletion appears to be a segregating polymorphism
with a single founder. In the Kirov et al. (9) study, the NRXN1 deletion they found was scored
as a segregating polymorphism as it was present in a mother and son; in the Walsh et al. (11)
study, it was found in a pair of MZ twins, with the parents not tested, so it is unclear if it arose
by a de novo event. These deletions may still be predominantly de novo as in the cases found
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by Kirov et al. (9) the deletion in the mother could have occurred de novo in a transmission
from a grandparent and subsequently been transmitted to her offspring; strong negative
selection pressure (the reduced fecundity in male schizophrenics) would then mean that this
deletion is quickly extinguished from the population. Reduced fecundity is well established in
schizophrenia, and earlier onset (such as appears to occur in many cases with large CNVs) is
also associated with lower fecundity. Although this is seen in both males and females, it is
more pronounced in males (20-22). As Bassett et al. (20) suggest, these epidemiological
observations are consistent with ‘a high mutation rate, consistent with unstable mutations, to
explain the high prevalence of schizophrenia’.
Heterogeneity of deletions and potential impact on the complex splicing of neurexin
The heterogeneity of the deletions we have identified at the NRXN1 locus also presents
difficulties when it comes to assessing association with schizophrenia. Caution is needed in
interpreting these results as the association we found was not significant when all CNVs were
examined collectively, and required conditioning on exon-disrupting deletions. It is likely that
pathogenicity of the deletions and duplications at this locus will vary, depending on the
functional importance of the DNA deleted. Conditioning on exons is the simplest method of
addressing this, as protein structure and splicing will be affected, and under this test the
association between exonic deletions and schizophrenia in our sample is highly significant.
The complexity of neurexin regulation at the level of alternative splicing has already been
suggested, with six splice sites with perhaps 1000 isoforms (23) and the potential to
theoretically generate over 2000 isoforms encoding variant extracellular domains (24).
Although the exact impact of deletions of the first exons of NRXN1a on alternative splicing
is unclear, it is possible that the expression of alternative NRXN1 isoforms may compensate
for the loss of the NRXN1a transcript. It is interesting that the first exon of NRXN1a-2 seems
to be deleted in the small founder deletion observed in 24 subjects most of whom were controls.
Considering the very low levels of expression of NRXN1a-2, and its frequent deletion in
controls, we therefore suggest that NRXN1a-2 may have a very limited biological role in
Neurexin signalling. However, activity of the NRXN1a-2 isoform may become significant
against a background of deletion of the other Neurexin isoforms. In such circumstances, even
low-level dominant negative activity may become biologically relevant. As most known
Neurexin interactions are extracellular it is unclear if NRXN1a-2 has any function, although
if it is secreted it may exert a dominant negative effect by competitive binding with NRXN1a
interactors; alternatively improper cellular localization of NRXN1a-2 may also be deleterious.
Evidence for the NRXN1a-3 isoform is much less conclusive than other isoforms as it shares
all exons with exons 4–18 of NRXN1a. This excludes the possibility of differentiation of
NRXN1a and NRXN1a-3 by the expression analysis. There is a high level of mammalian
conservation before the first exon of NRXN1a-3 and there is also EST evidence to support the
existence of this isoform although, these ESTs cannot be clearly differentiated from NRXN1a
transcripts. The putative initiation methionine of the NRXN1a-3 isoform correlates with
NRXN1a Met321 roughly a third of the way into Laminin G domain 2 of the protein (see Fig.
3).
The truncated domain of NRXN1a-3 may not be functional as it has lost a critical Ca2+ binding
residue Asp306, which also mediates interactions with Neurexophilins (25,26). Loss of
Neurexophilin interactions may be particularly relevant to schizophrenia pathology, as
Neurexophilin-3 knockout mice show no anatomical defects, but remarkable functional
abnormalities in sensory information processing and motor coordination, evident by increased
startle response, reduced prepulse inhibition and poor Rotarod performance (27). It is tempting
to speculate that the disruption of NRXN1/Neurexophilin interactions that are likely to be seen
in all our observed exonic deletions may explain some of the pathology of schizophrenia. More
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detailed bioinformatic and functional biology may be able to shed further light on the genotype–
phenotype and functional consequences of various deletions at this locus.
Haploinsufficieny as a mechanism of pathogenicity
In addition to the disruption of splicing and the effects of this on the interaction of neurexin
proteins with protein partners, the association between NRXN1 deletions and schizophrenia
could also result from haploinsufficiency of the gene. Given that we see a strong association
when conditioning on disruption of an exon in the two known RefSeq sequences for NRXN1,
and the most common and smallest deletion of intron-only sequence [although the first exon
of the novel splice variant NRXN1a-2 (Fig. 3) appears to be deleted] shows a founder effect
and is thus not likely to be under strong negative selection pressure, it is not likely that all the
deletions we found at the NRXN1 locus have the same biological effect on disrupting the
function of NRXN1, and some will probably be neutral variants. Intron-only deletions could of
course disrupt splicing or remove essential regulatory elements such as splicing enhancers and/
or silencers, and the neurexin 1 gene is extensively spliced, with more than 2000 potential
isoforms (23). In order to provide further information on the effects of these deletions, it will
be necessary to analyse mRNA and protein expression, for example, using relative allelic
expression of non-deleted exons in NRXN1 mRNA to demonstrate which deletions result in
haploinsufficiency.
Founder effects and the distribution of neurexin 1 deletions in Europe
There is also a question of how to treat the sample with regard to geographical origin, as most
of the deletions in cases were from the German population (6/14; 43%) although, of course, as
25% of the examined patients were German in origin, this over-representation could have
occurred by chance. If these deletions are truly recurrent, and depend on a random mechanism
involving DNA sequences or recombination rates in the region, one would not expect
significant geographic clustering. Clustering may indicate deletions which are segregating in
the population, perhaps from an ancestral founder, or a pre-mutation or polymorphic DNA
sequence which increases the probability of a de novo event and is more prevalent in one
population than others. A haplotype analysis that we performed on the German samples with
deletions showed no excess sharing of alleles around the NRXN1 5′-region, which, when
combined with the observed heterogeneity of the deletions, strongly opposes a founder effect.
The most common deletion, which occurred in 29 subjects, was also the smallest and showed
evidence of a single founder. This may be a neutral segregating polymorphism which does not
significantly affect NRXN1 function and is not relevant to risk of schizophrenia.
Penetrance and frequency of neurexin deletions
Rare NRXN1 deletions have also been reported in the normal population. Pinto et al. (28) found
an intronic 71 kb deletion in a sample of 506 unrelated healthy individuals from Northern
Germany and 270 HapMap individuals (chr2:50,826,443-50, 897,556) which overlaps with
some of the intronic deletions seen in the present study, and both Redon et al. (29)
(chr2:50,643,118-50,686,339 Build 36) and Wong et al. (30) found similar sized deletions
(chr2:50,651,965-50,714,553) in single control subjects, one of which removes four exons of
the gene. These subjects have no known neuropsychiatric phenotype, consistent with the notion
that although deletions of NRXN1 are strongly associated with mental illness, they are not
necessarily fully penetrant, as seen in the data from the present study, and some individuals
may be able to compensate for dosage loss, for example, through a high expressing residual
copy of the gene, another modifying locus, or an environmental event which results in a gene-
by-environment interaction pathway to disease.
The 2p16.3 deletions we found are moderately rare, occurring at a rate of about 4.7 per 1000
cases, and, from the control population in the present study, at ~0.15% of live births. This is
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substantially higher than the VCFS deletion, found in ~0.01% of live births (31), making it one
of the most common gene deletions known. However, if we exclude the deletions in NRXN1
which do not disrupt exons and are less likely to be pathogenic, the deletion rate is 2.4 per 1000
(0.24%) in the cases compared to 0.015% in the controls, a rate very comparable to VCFS
deletions.
The structural mutations showing association to schizophrenia disrupt the NRXN1 gene, rather
than deleting or duplicating the entire gene. A generalized study of structural mutations by
Lupski and Stankiewicz (32) showed that such mutations are much more likely to have
biological consequences, in our case deletion of exons from the most prevalent NRXN1a
isoform may favour the expression of the rarer NRXN1a-2 and NRXN1a-3 isoforms, which
may possibly exert a dominant negative effect on Neurexin signalling, particularly through
Neurexophilins.
The odds ratio (~10-fold increase in risk) is less than that associated with the VCFS deletion,
where ~25% of subjects develop psychosis and the odds ratio for the VCFS deletion is about
30, assuming a population rate of non-VCFS deletion schizophrenia of ~1% (33). It is possible
that there are many more CNVs in the human genome which can cause schizophrenia, and
these could make up a significant proportion of genetic risk for the disease which could prove
clinically useful, for example, through genetic testing.
Potential deletion mechanisms at the NRXN1 locus
The nature of the loci studied here raises questions about the mechanisms underlying CNV
events. Many chromosomal rearrangements are not random events, but the result of genome
architecture that may create inherent instability (34), such as the long LCRs typical of many
other regions where CNVs have been reported. These result in non-allelic homologous
recombination (NAHR) between the LCRs on opposite flanks of the deleted/duplicated
segment. However, several genomic disorders are associated with rearrangements whose
breakpoints do not cluster within LCRs, as in the case of NRXN1 deletions. There we see no
evidence of LCRs flanking the breakpoints, nor do we find common breakpoints or evidence
of sequence duplications in the region. The LD pattern is particularly unstructured in the 5′-
end of the gene and the upstream region where we observe the deletions. This may suggest
increased recombination rate in the region that may be related to the aggregation of deletions
at the site, through an unknown mechanism. There are suggestions that CNV events are also
associated with the presence of processed pseudogenes, the presence of microsatellites and
nonhomologous end joining mediated by micro-homologies (<25 bp homology), especially in
subtelomeric regions, or DNA replication-based mechanisms, rather than a NAHR mechanism
mediated by larger matching repeats (32,35,36). Similar to NRXN1, CNVs in the PLP1 gene
do not show common breakpoints. Lee et al. (36) examined this locus and uncovered evidence
for sequence complexity at some junctions, consistent with a DNA replication-based
mechanism of CNV formation (replication Fork Stalling and Template Switching, FoSTeS).
This mechanism might explain the non-recurrent apparently de novo deletions with multiple
breakpoints seen in NRXN1. To examine this further, we performed long range phasing analysis
(37) of the single case of autism known to have a de novo NRXN1 deletion in the Icelandic
population. This showed that no recombinations had occurred in the region around the de
novo deletion (data not shown), providing further evidence against a role for an NAHR
mechanism in this case.
Schizophrenia and autism: aetiological overlap?
The data from our sample of cases and controls provide support for a role for deletions within
the NRXN1 gene in schizophrenia, and raise the concept that this disorder has shared genetic
risk factors with autism. If this is indeed the case, it would change the way the distinctions
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between the diseases is formulated, and therefore has profound clinical implications. In support
of this are previous observations such as the VCFS deletions at 22q11.2, which appear to
increase the risk of both autism (38) and schizophrenia (33,39), and data from the present and
other studies indicating that neurexin deletions are seen in both disorders as well as other
behavioural syndromes (9,11,15-19). On the other hand, the concept of diagnostic overlap
between the two disorders is controversial: while Rzhetsky et al. (40) provide some theoretical
support for aetiological overlap, evidence from clinical and epidemiological study is less
supportive (41,42). In general, there have been few genetic and epidemio-logical studies of
potential overlap between the disorders, and the present and other studies point the way towards
more comprehensive evaluation of potential diagnostic overlap between these and indeed other
psychiatric disorders in the future.
MATERIALS AND METHODS
Samples
A total of 2977 affected and 33 746 controls from six European populations were successfully
examined for CNVs at the NRXN1, NRXN2 and NRXN3 loci studied here (Supplementary
Material, Table S1); 1435 schizophrenia patients and 28 554 control individuals from the
Iceland, Scotland, Germany, England, Italy and Finland (The SGENE sample;
http://www.SGENE.eu), 491 affected and 881 controls from Bonn, Germany, 806 cases and
4039 controls from the Netherlands and 245 cases and 272 controls from Norway. For a full
description of samples, see Supplementary Information. Ethical approval was obtained from
the local Ethics Committees. All participants gave written informed consent.
The SGENE samples were typed on the HumanHap300 BeadArray™ (Illumina, San Diego,
CA, USA) at deCODE genetics. The samples from Bonn were typed at Bonn University on
HumanHap550v3 BeadArray™ (Illumina, San Diego, CA, USA). The Dutch samples from
Utrecht University were genotyped at the University of California, Los Angeles, on
HumanHap550v3 BeadArray™. The remaining Dutch samples were genotyped at deCODE
genetics on HumanHap300 BeadArray™. The Norwegian samples were genotyped on
Affymetrix GeneChip GenomeWide SNP 6.0 array and analysed using the Affymetrix Power
Tools 1.8.0. Samples with Contrast QC below 0.4 were excluded as recommended by the
manufacturer.
CNV detection
DosageMiner software, developed at deCODE genetics, and QuantiSNP (43; see below for
description) were used to identify deletions and duplications around the regions reported by
Kirov et al. (9) and Walsh et al. (11) in all samples except the Norwegian sample, where only
QuantiSNP was used. DosageMiner, described in detail elsewhere (12), uses the intensities
from SNP probes on the Illumina microarrays to estimate copy number of genomic regions,
and models factors such as SNP effect, sample effect and GC-content the in neighbouring
region to normalize the intensities. The software then automatically registers SNP loci where
intensities fall above or below an empirical threshold. We conditioned our search to include
only CNVs with 10 or more contiguous markers registered as duplicated or deleted by
DosageMiner, in order to reduce the level of false positive CNVs identified by the software.
We then inspected the intensities by eye for all samples with a CNV identified by the software.
We used SNP genotypes for further confirmation in case of deletions by conditioning on
homozygosity for all markers within the boundaries of the suspected CNV. In some instances,
the actual CNV may be shorter than 10 contiguous markers, because the boundaries called by
DosageMiner may not always be entirely accurate.
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The QuantiSNP software, developed at the Wellcome Trust Centre for Human Genetics and
at the University of Oxford (http://www.well.ox.ac.uk/QuantiSNP/), relies on an Objective
Bayes Hidden–Markov model to estimate copy number variations (43). In this model, the
hidden states denote the unknown copy number at the inspected SNPs. Genotype data were
used to compute different states. Based on the ratio of fluorescent dye ratios (logR) and
stretches of homozygosity, the algorithm computes a Bayes factor that is used to calibrate the
model to a fixed type I (false-positive) error rate. A Bayes factor threshold of 10 is considered
as a promising value for the possible presence of a CNV. Usually, such values occur when 5–
10 consecutive SNPs are deleted/duplicated. Differences in GC base pairs may result in biased
hybridization behaviour of SNP probes bearing the risk of miscalling genotypes. To normalize
for this, QuantiSNP assigns a locus-specific GC value to each probe. Again, all potential CNVs
detected were subsequently visually inspected and confirmed using the Bead-Studio software
(Illumina, San Diego, CA, USA). We used the Cochran–Mantel–Haenszel exact test for the
association analysis, which includes a correction for population of origin in the analysis. In
order to condition on exons, we scored a CNV as exon-disruption if it overlapped any known
exonic sequence in NRXN1, based on reviewed sequence from Human mRNA from RefSeq
(NM_004801 for NRXN1-alpha). Long-range phasing analysis to detect recombination events
in the Icelandic case of autism with a de novo NRXN1 deletion was performed using the method
of Kong et al. (37).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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NOTE ADDED IN PROOF
Some of the data published in this paper (submitted May 16 2008; accepted October 22 2008)
has also appeared in a parallel publication taking a discovery approach rather than a candidate
gene approach (Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E; Genetic Risk
and Outcome in Psychosis (GROUP) Consortium, Sabatti C, Geurts van Kessel A, Brunner
HG, Ophoff RA, Veltman JA. Recurrent CNVs disrupt three candidate genes in schizophrenia
patients. Am J Hum Genet. 2008 Oct;83(4):504–510; submitted July 2nd 2008; accepted
October 20 2008). Specifically, the 54+752 cases tested Vrijenhoek et al. are the same 806
cases from The Netherlands reported in the present paper, and the Utrecht controls (n=706) of
our Dutch controls in the present study are also the same. For the purposes of clarification and
to assist meta analysis, we have calculated the results without the Dutch sample as follows.
For exon-disrupting cnvs without the Dutch sample, we found the following (Country, aff-
carriers/aff-non-carriers, ctrl-carriers/ctrl-non-carriers) Germany 3/684, 0/1078; Iceland
0/648, 4/27747; Italy 1/85, 0/91; Finland 1/62, 1/149. The P-value = 0.04, and the alternative
hypothesis: true common odds ratio is not equal to 1, 95 percent confidence interval:
0.853866-38.921971. Common odds ratio: 5.4. This should be borne in mind for combined or
meta analysis of data.
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Figure 1.
UCSC browser output showing the positions of the 2p16.3 CNVs from the Kirov et al. (2008),
Walsh et al. (2008), Friedman et al. (2008) and Szatzmar et al. (2008) studies (blue lines)
relative to the NRXN1 gene, and the CNVs discovered in the present study (schizophrenia, red
lines; other psychiatric diagnoses, brown lines; controls, green lines). The majority of the
discovered CNVs are deletions, asterisks indicate duplications. Markers from the Illumina 300
K and 550 K arrays, segmental duplications of >1000 bp as well as LD structure of the Hapmap
CEU sample (r2) is also shown.
Rujescu et al. Page 13
Hum Mol Genet. Author manuscript; available in PMC 2009 September 1.
U
KPM
C
 Funders G
roup Author M
anuscript
U
KPM
C
 Funders G
roup Author M
anuscript
Figure 2.
UCSC browser output showing the positions of exon-disrupting CNVs discovered in the study
relative to the 2p16.3 CNVs from the Kirov et al. (2008), Walsh et al. (2008), Friedman et
al. (2008) and Szatzmar et al. (2008) studies and known (schizophrenia, red lines; other
psychiatric diagnoses, brown lines; controls, green lines; previously described CNVs, blue
lines). The four putative Neurexin isoforms are shown below the deletions, along with protein
domains aligned to genomic sequence.
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Figure 3.
Protein domain organization of Neurexin 1 isoforms. NRXN1a contains an N-terminal signal
peptide, six laminin G (LamG) domains, three epidermal growth factor-like (EGF) domains,
a transmembrane domain and a short cytoplasmic domain. NRXN1b contains a different signal
peptide, but shares the last LamG domain, transmembrane domain and cytoplasmic domain
with NRXN1a. NRXN1a-2 shares the 2nd, 3rd, 4th and 5th LamG domains and the 2nd and
3rd EGF domains with NRXN1a, but does not contain a signal peptide or transmembrane
domain. NRXN1a-3 has no signal peptide and has a truncated version of the 2nd LamG domain
but shares all remaining domains with NRXN1a. The five regions in the NRXN1 gene where
alternative splicing occurs, leading to insertion or deletion of amino acids is indicated by arrows
(SS no. 1–5). Protein domain annotation was generated using SMART
(http://smart.embl-heidelberg.de/), using swissprot accessions Q9ULB1 (NRXN1a) and
P58400 (NRXN1b) and translations from the genbank transcript AK093260 (NRXN1a-2) and
Ensembl transcript ENST00000331040 (NRXN1a-3).
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